Your session is about to expire
← Back to Search
Acupressure for Peripheral Neuropathy
N/A
Recruiting
Led By Nada Lukkahatai, PHD, MSN, RN
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have received a medication in one of the following categories: platinum-based, vinca alkaloids, bortezomib, eribulin, and/or taxanes
Have completed their course of chemotherapy three months or more before enrollment
Must not have
Prior celiac plexus block or other neurolytic pain control treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will evaluate auricular point acupressure (APA) on chemotherapy-induced neuropathy (CIN), with the goal of understanding its efficacy and underlying mechanism(s).
Who is the study for?
This trial is for cancer patients over 18 who've finished chemotherapy with specific drugs at least three months ago and are experiencing moderate to severe neuropathy pain or numbness. It's not for those using investigational pain agents, drug delivery implants, have latex allergies, prior neurolytic treatments, or pre-existing conditions causing similar symptoms.
What is being tested?
The study tests Auricular Point Acupressure (APA) for managing chemotherapy-induced neuropathy. Participants will be randomly assigned to receive APA via a virtual app or in-person training, sham APA as a placebo control, or usual care without APA intervention.
What are the potential side effects?
Since the intervention involves non-invasive acupressure rather than medication, significant side effects are not anticipated. However, some participants might experience minor discomfort or skin irritation at the site of acupressure application.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been treated with specific cancer drugs like platinum or taxanes.
Select...
I finished my chemotherapy over three months ago.
Select...
I have nerve damage from chemotherapy or it worsened after treatment.
Select...
I have had pain, numbness, or tingling in my limbs rated 4 or higher last week.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had a celiac plexus block or similar pain treatment.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in numbness as assessed by the Brief Pain Inventory
Change in pain severity as assessed by the Brief Pain Inventory
Change in physical function as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) 29
+1 moreSecondary study objectives
Change in anti-inflammatory cytokines as assessed by serum cytokine biomarkers
Change in pro-inflammatory cytokines as assessed by serum cytokine biomarkers
Change of brain activity as assessed by fMRI Neuroimaging
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Virtual Auricular Point Acupressure (vAPA)Experimental Treatment2 Interventions
The vAPA arm will self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement and will receive one zoom session for APA coaching one week after the baseline visit.
Group II: Auricular Point Acupressure (APA)Experimental Treatment2 Interventions
The APA arm will receive in-person weekly treatments and a self-guided smartphone application with videos for understanding and administering APA. The APA arm will receive one in-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points, as well as one zoom meeting 1 week after the first visit to coach participant and/or caregiver on seed placement.
Group III: Usual Care ControlActive Control1 Intervention
Usual Care arm will continue with their usual care.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterOTHER
3,065 Previous Clinical Trials
1,802,023 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,917 Previous Clinical Trials
41,014,240 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,323 Previous Clinical Trials
14,874,082 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been treated with specific cancer drugs like platinum or taxanes.I have had painful tingling in my limbs before chemotherapy due to other causes.I finished my chemotherapy over three months ago.I have had a celiac plexus block or similar pain treatment.I haven't used experimental pain medication in the last 30 days.I am 18 years old or older with cancer.I have nerve damage from chemotherapy or it worsened after treatment.I have had pain, numbness, or tingling in my limbs rated 4 or higher last week.
Research Study Groups:
This trial has the following groups:- Group 1: Virtual Auricular Point Acupressure (vAPA)
- Group 2: Auricular Point Acupressure (APA)
- Group 3: Usual Care Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger